Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tiantan Biological Products To Acquire Chengdu Rongsheng Pharmaceuticals

This article was originally published in PharmAsia News

Executive Summary

Tiantan Biological Products will issue 18 to 22 million shares to China National Biotec Group's Chengdu Institute of Biological Products to acquire the latter's 51 percent stake in Chengdu Rongsheng Pharmaceuticals. At the same time, Tiantan will issue shares to CNBG's subsidiary National Vaccine & Serum Institute to obtain its 68,512.52-square-meter industrial land. Both issued shares are priced at RMB 14.43 per share. Furthermore, Tiantan will issue 50 to 75 million private shares to raise funds not exceeding RMB 1.5 billion ($218 million), of which RMB 200 million ($29.1 million) will be used to purchase Chengdu government's 39 percent stake in Chengdu Rongsheng and to invest in Tiantan's Daxing production base establishment. After the whole exercise, Tiantan will become China's largest blood-products company. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts